Postmenopausal endometriosis

Tevfik Yoldemir

DOI: https://doi.org/10.1080/09513590.2024.2441299

2024-12-14

Gynecological Endocrinology

Abstract:Untreated symptomatic endometriosis has adverse life impacts: achievements, education, family, career, social life, personal relationships, emotional health, and quality of life starting at adolescence and occurring even beyond menopause. Impaired daily activities, fatigue, sexual dysfunction, physical changes due to treatment, emotional distress, depression, anxiety, and comorbidities lead to worsen quality of life [ Citation 1 ]. While endometriosis is seen in almost 10% of women during perimenopausal years, its prevalence after menopause is estimated to be 2–4%. One of the differential diagnoses of pelvic pain in postmenopausal women is endometriosis. Postmenopausal endometriosis might occur de novo in women who never had endometriosis symptoms or may recur after the initiation or continuation of menopausal hormonal therapy (MHT) [ Citation 2 ]. Endometriosis lesion can affect different organs such as the bladder, ureter, intestines, and thorax. The recurrence of postmenopausal endometriosis might be seen after estrogen-only or estrogen combined with progestin MHT [ Citation 3 ]. Recurrence has been reported with low-dose, standard dose, high dose estrogen alone and also combined estrogen and progestogen regimens. Similarly, recurrence has also been seen with the use of low and standard dose tibolone [ Citation 2 ]. When endometriosis recurs in the postmenopausal period, the common symptoms are flank and pelvic pain, vaginal bleeding and dyspareunia.

endocrinology & metabolism,obstetrics & gynecology